Styryl-based and tricyclic compounds as potential anti-prion agents

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Chung, Erika ^a   Prelli, Frances ^a   Dealler, Stephen ^b   Lee, Woo Sirl ^c   Chang, Young Tae ^c,d   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Microsens Biotechnology Ltd   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; FLUPHENAZINE; PRION PROTEIN; STYRENE DERIVATIVE; TRIMIPRAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; ASTROCYTOSIS; ASYMPTOMATIC INFECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRION DISEASE; TISSUE CULTURE; ANIMAL; METABOLISM; PRION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALIA; MUS;

AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLUPHENAZINE; MICE; PRION DISEASES; PRIONS; PRPC PROTEINS; PRPSC PROTEINS; TRIMIPRAMINE;

EID: 80052821738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024844     Document Type: Article

References (33)

1. Norrby E, (2011) Prions and protein folding diseases. J Intern Med in press.
2. Wisniewski T, Goni F, (2010) Immunomodulation for Prion and Prion Related Diseases. Expert Rev Vaccines 9: 1441-1452.
3. Aguzzi A, Sigurdson C, Heikenwalder M, (2008) Molecular Mechanisms of Prion Pathogenesis. Annu Rev Pathol 3: 11-40.
4. Cobb NJ, Surewicz WK, (2009) Prion diseases and their biochemical mechanisms. Biochem 48: 2574-2585.
5. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, et al. (2008) A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 63: 697-708.
6. Trevitt CR, Collinge J, (2006) A systematic review of prion therapeutics in experimental models. Brain 129: 2241-2265.
7. Brown P, (2008) Transmissible spongiform encephalopathy in the 21st century: neuroscience for the clinical neurologist. Neurol 70: 713-722.
8. Brazier MW, Wall VA, Brazier BW, Masters CL, Collins SJ, (2009) Therapeutic interventions ameliorating prion disease. Expert Rev Anti Infect Ther 7: 83-105.
9. Li L, Napper S, Cashman NR, (2010) Immunotherapy for prion diseases: opportunities and obstacles. Immunotherapy 2: 269-282.
10. Marsh RF, Kincaid AE, Bessen RA, Bartz JC, (2005) Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). J Virol 79: 13794-13796.
11. Sigurdson CJ, (2008) A prion disease of cervids: chronic wasting disease. Vet Res 39: 41.
12. Race B, Meade-White KD, Miller MW, Barbian KD, Rubenstein R, et al. (2009) Susceptibilities of nonhuman primates to chronic wasting disease. Emerg Infect Dis 15: 1366-1376.
13. Poli G, Martino PA, Villa S, Carcassola G, Giannino ML, et al. (2004) Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung 54: 406-415.
14. Ishikawa K, Kudo Y, Nishida N, Suemoto T, Sawada T, et al. (2006) Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies. J Neurochem 99: 198-205.
15. Webb S, Lekishvili T, Loeschner C, Sellarajah S, Prelli F, et al. (2007) Mechanistic insights into prion curing by novel anti-prion compounds. J Virol 81: 10729-10741.
16. Kawasaki Y, Kawagoe K, Chen CJ, Teruya K, Sakasegawa Y, et al. (2007) Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 81: 12889-12898.
17. Korth C, May BC, Cohen FE, Prusiner SB, (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98: 9836-9841.
18. Appleby BS, (2009) Psychotropic medications and the treatment of human prion diseases. CNS Neurol Disord Drug Targets 8: 353-362.
19. Li Q, Min J, Namm J, Kim E, Lui R, et al. (2007) Stryl-based compounds as potential in vivo imaging agents for β-amyloid plaques. Chembiochem 8: 1679-1687.
20. Sadowski MJ, Pankiewicz J, Prelli F, Scholtzova H, Spinner DS, et al. (2009) Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis 34: 267-278.
21. Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, et al. (2006) Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 24: 2635-2647.
22. Prusiner SB, (2001) Neurodegenerative diseases and prions. N Eng J Med 344: 1516-1526.
23. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, et al. (2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77: 10288-10294.
24. Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, et al. (2003) Evaluation of quinacrine treatment for prion diseases. J Virol 77: 8462-8469.
25. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, et al. (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52: 503-506.
26. Follette P, (2003) New perspectives for prion therapeutics meeting. Prion disease treatment's early promise unravels. Science 299: 191-192.
27. Ingrosso L, Ladogana A, Pocchiari M, (1995) Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 69: 506-508.
28. Spinner DS, Kascsak RB, LaFauci G, Meeker HC, Ye X, et al. (2007) CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol 14: 36-43.
29. Goni F, Prelli F, Schreiber F, Scholtzova H, Chung E, et al. (2008) High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice. Neurosci 153: 679-686.
30. Ye X, Scallet AC, Kascsak RJ, Carp RI, (1998) Astrocytosis and amyloid deposition in scrapie-infected hamsters. Brain Res 809: 277-287.
31. Chung E, Ji Y, Sun Y, Kascsak R, Kascsak RB, et al. (2010) Anti-PrPC monoclonal antibody infusion as a novel treatment for Aβ oligomer cognitive cognitive deficits. BMC Neuroscience 11: 130.
32. Sadowski M, Pankiewicz J, Scholtzova H, Mehta P, Prelli F, et al. (2006) Blocking the apolipoproteinE/Amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice. Proc Natl Acad Sci (USA) 103: 18787-18792.
33. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, et al. (2004) Blocking the apolipoprotein E/ß-amyloid interaction reduces β-amyloid toxicity and decreases β-amyloid load in transgenic mice. Am J Pathol 165: 937-948.